

Article

Not peer-reviewed version

Clinical Signs at Diagnosis and Comorbidities in a Large Cohort of Patients with Lipedema in Spain

[José Luis Simarro Blasco](#)*, [Sandro Michelini](#), [Miguel Andrés-Gasco](#), Alberto Lebrero García, [Desirée Ortega Abad](#), José Margalejo Lombardo, Julian Bug Vargas, Jesús Tomás Sánchez-Costa, María Auxiliadora Martín Martínez

Posted Date: 17 October 2025

doi: 10.20944/preprints202510.1397.v1

Keywords: Lipedema; diagnosis; signs and symptoms; morbidity



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

Clinical Signs at Diagnosis and Comorbidities in a Large Cohort of Patients with Lipedema in Spain

José Luis Simarro Blasco ^{1,*}, Sandro Michelini ², Miguel Andrés-Gasco ¹, Alberto Lebrero García ¹, Desirée Ortega Abad ¹, José Margalejo varrdo ¹, Julian Bug Vargas ¹, Jesús Tomás Sánchez-Costa ³ and María Auxiliadora Martín Martínez ³

¹ Instituto del Lipedema y de la Mujer, Calle de Modesto Lafuente, 45, 28003 Madrid, 28003, Madrid, Spain

² Institute san Giovanni Battista Hospital, Via Luigi Ercole Morselli, 13, 00148, Rome, Italy

³ Investigación en Salud y Calidad Asistencial (INSyCA), 28860, Madrid, Spain

* Correspondence: drsimarro@institutolipedema.com

Abstract

Background/Objectives: Lipedema is a chronic disorder that affects almost exclusively women and is characterized by bilateral, symmetrical accumulation of subcutaneous fat, typically in the buttocks, hips, and lower limbs, and in some cases the arms. The primary objective of this study was to describe the clinical and anatomical manifestations of lipedema, together with the associated physical and psychological comorbidities, in a large Spanish cohort. **Methods:** Descriptive study of 1,803 patients aged ≥ 17 years who attended two clinics in Spain between January 2022 and November 2024. **Results:** The mean age was 42.9 years (SD: 11.3), and 60.6% of patients were diagnosed during their reproductive years. The mean body mass index was 28.6 (SD: 6.2), and 87.6% presented a gynoid fat distribution. A total of 46.6% were classified as Schingale stage IV or V. The most frequent comorbidities were chronic low-grade inflammatory alterations and connective tissue damage. Particularly intestinal hyperpermeability (99%), bilateral trochanteritis (97.4%), iliotibial band involvement, and ligamentous hyperlaxity (95.8%). Thyroid disorders, inflammatory ovarian dysfunction, and psychological impairment were also common. **Conclusions:** Lipedema is a complex condition that extends beyond lower-limb adipose tissue and is associated with multiple comorbidities. This study also introduces a novel clinical examination approach that may assist clinicians in establishing a rapid, straightforward and effective diagnosis.

Keywords: Lipedema; diagnosis; signs and symptoms; morbidity

1. Introduction

Lipedema is a chronic disorder that predominantly affects women and is characterized by a bilateral and symmetrical increase in the volume of appendicular subcutaneous adipose tissue, with a nodular and fibrotic appearance, most frequently in the buttocks, hips and lower limbs (1). In approximately 30% of cases, the upper limbs may also be affected. Although lipedema was first described by Allen and Hines in 1940 (2), Lipedema was proposed as a disease by the World Health Organization (WHO) (3) in May 2018 and was officially accepted as such on January 1, 2022, as an independent clinical entity in the International Classification of Diseases (EF02.2; ICD-11).

This condition remains poorly understood and is often confused with other clinical entities such as lymphedema, phlebedema, obesity, lipodystrophy, obesity-induced lymphedema (OIL), and Madelung's disease (4,5,6). A recent review conducted in 2025 (7) highlights the persistent lack of knowledge regarding the management of this disorder and underscores the urgent need for high-quality clinical trials to improve understanding and to explore optimal medical and surgical therapeutic options for affected patients. This knowledge gap contributes to significant delays in diagnosis, high rates of unnecessary consultations with other specialists, deterioration in quality of life, and a substantial psychological and emotional impact on patients (8).

Data on the prevalence of this disorder are very limited and underestimated. In Spain, such information is unavailable, whereas in the United States, prevalence data in children indicate rates of up to 6.5% (9). In Germany, the frequency of this condition has also been investigated, with reported prevalence ranging from 7% to 9.7% (10).

Another limitation of this disorder is the absence of validated diagnostic criteria or a reliable and readily accessible biomarker for lipedema, which renders the diagnosis fundamentally clinical and dependent on the clinician's experience.

Coinciding with the WHO's designation of lipedema as a disease in 2018, a literature review was published outlining the clinical features, diagnosis, and management of this condition (6). The review emphasizes the importance of a thorough anamnesis to establish disproportionate fat distribution, the limited impact of weight loss on fat distribution, pain, tenderness to touch, and the lack of pain relief with limb elevation. Following the anamnesis, a comprehensive physical examination should be performed to determine the affected sites (thigh, leg, arm, and/or forearm) and to assess additional criteria such as tenderness on palpation and the presence of distal fat over the knee tendons. Since then, no large-scale studies have been published to confirm the presence of these criteria or to evaluate the distribution of their frequencies.

In addition to diagnostic criteria, a crucial aspect of this disorder is the associated comorbidities and impact on quality of life and mental health. A recent study by Luta X et al. demonstrated that pain affected nearly 90% (87.9%) of patients in their cohort, and poor physical and mental well-being was reported in 71.5% and 67.4% of patients, respectively (12). Women with lipedema face not only physical symptoms but also high levels of social stigmatization and emotional challenges due to a lack of understanding by healthcare professionals (13). Many patients report feelings of frustration, low self-esteem, and anxiety resulting from the absence of effective treatment options and the misperception of their condition as obesity (14,15). These challenges are amplified in patients with more advanced stages of the disease, who often perceive that they are not taken seriously and are only offered advice on diet and lifestyle due to misdiagnosis as obesity or failure to consider a lipedema diagnosis (16).

Lipedema shows strong familial aggregation and likely autosomal-dominant inheritance with sex limitation. Early pedigree studies supported a genetic basis, later strengthened by candidate-gene evidence—most notably a missense variant in *AKR1C1* impacting progesterone metabolism in a multigenerational family—and by genome-wide signals implicating loci related to adipose/vascular biology (*VEGFA*, *GRB14-COBLL1*). Together, these data indicate a heritable, polygenic/heterogeneous architecture consistent with clinical clustering in women (17-20).

In 2016, the first clinical guideline was published in the Netherlands, establishing a series of clinical criteria for the diagnosis of lipedema, as well as an attempt to define a therapeutic algorithm (21). In addition to diagnostic criteria, the guideline also defined a "basic set" of disease-specific criteria and clinimetric measures to consistently identify disease-related disability and impairments in daily functioning. To further advance understanding of the clinical signs and symptoms that characterize lipedema and distribution in affected patients, this descriptive study was conducted using one of the largest cohorts of patients with lipedema worldwide.

2. Methods

A retrospective, observational, descriptive study based on the review of medical records of patients over 17 years of age with a clinical diagnosis of lipedema who attended the Instituto del Lipedema y de la Mujer clinics in Madrid and Barcelona between January 2022 and November 2024. As part of routine clinical practice during the diagnostic visit, patients underwent physical examinations and assessments, including multifrequency segmental bioelectrical impedance analysis (TANITA 480 MA) to evaluate fat mass, muscle mass, and body water both overall and individually for each of the five body segments (limbs and trunk/abdomen) (22), as well as bicipital skinfold caliper measurements. The following were evaluated: tender points, painful areas, pseudo-pinch sign, partial fine sensory loss at the pertrochanteric region, and neuropathic pain. Figure 1.




Figure 1. (photographs 1, 2, 3, 4). Physical examination of lipedema: Simarro's tender points, painful areas, the "false prick" sign, and loss of fine sensation.

Photograph 1: The discontinuous black lines show the pathway of the saphenous nerve. The space enclosed within the blue line is the great saphenous vein compartment (GSphC). The areas marked in red are the areas positive for the "false prick" sign, and the black arrows indicate the Simarro points that are painful upon deep pinching.

Photograph 2: The pertrochanteric area shows a loss of fine sensitivity. The pathway is marked by black lines using a fine brush. The patient notices a loss of fine sensitivity when entering the indicated area and recovers it upon exiting.

Photograph 3: The discontinuous black lines refer to the pathway of the posterior ulnar nerve, and the space within the blue line corresponds to the posterior brachial compartment (PBC). The space within the red line refers to the area positive for the "false prick" sign, and the black arrows correspond to the area painful upon superficial pinching. The loss of fine sensitivity is explored by passing a fine brush along the black line, and the patient notes a loss of fine sensitivity when entering the indicated area and recovery upon exiting.

Photograph 4: Angle at which the sign of the "false prick" sign should be used within the areas marked with a red line.

The following comorbidities were recorded: intestinal hyperpermeability syndrome assessed with an ad hoc questionnaire (Table S1) (23-34); ligamentous hyperlaxity based on the Beighton test (Table S2) (35); inflammatory ovarian dysfunction (Table S3) (36-38); thyroid disease as determined by ultrasound; allergies, particularly to nickel; and eating disorders assessed using the validated Spanish versions of the Eating Attitudes Test-40 (EAT-40) (Table S4) (39) and the SCOFF questionnaire (Table S5) (40).

2.1. Variables and Operational Definitions

Sociodemographic variables were collected, including sex and age, as well as date of lipedema diagnosis. Anthropometric variables included weight (kg), height (cm), body mass index (BMI; weight (kg)/height (cm)²) and its categorization (normal weight [18.5–24.9], overweight I [25–27.9], overweight II [28–29.9], obesity type I [30–34.9], type II [35–39.9], type III [40–49.9], type IV [≥50], and underweight [<18.5]). The waist-to-hip ratio (WHR) was also recorded as an indicator of body fat distribution, classified as android pattern (predominant fat accumulation in the abdominal region,

thorax, and upper body) or gynoid pattern (fat accumulation in the hips, thighs, and buttocks). During the physical examination, deep pressure pain was assessed in both the proximal and distal portions of the Great Saphenous Compartment (GSphC), in addition to deep pressure pain in the Small Saphenous Compartment (SSphC), and superficial pressure pain in the Posterior Brachial Compartment (PBC) (Figure 1). Specific tender points were assessed along the GSphC: (1) deep medial supracondylar, (2) deep medial infracondylar, (3) deep medial supramalleolar, and in the superficial supra-olecranon area of the distal PBC (yes/no) (Figure 1). The pseudo-pinch sign was explored at two points along the GSphC and at one point in the PBC, as well as fine sensory loss at the petrochanteric region, the Kaposi-Stemmer sign (41), the presence of supramalleolar edema with and without pitting, and distal pretibial edema with and without pitting (Figure 1). Among comorbidities, intestinal hyperpermeability was assessed using a 26-item ad hoc questionnaire developed from a literature review and expert consensus (Table S1) (23-34). The cut-off score for identifying patients with intestinal hyperpermeability was 16 (see supplementary material). Ligamentous hyperlaxity was determined using the Beighton score (0-9) (35) (see supplementary material). The presence of bilateral trochanteritis, iliotibial band involvement (tensor fasciae latae), recurrent episodes of ankle twisting without sprain, associated with mechanical instability, and other comorbidities were also evaluated. These included clinically confirmed nickel skin allergy, thyroid disease as assessed by ultrasound (classified as echogenicity alterations, multinodular goiter, multinodular thyroid, or thyroid nodules), and inflammatory ovarian dysfunction, assessed using a four-item ad hoc questionnaire (36-38) (Table S3), in which the condition was diagnosed with three positive responses. Pain in paratibial and/or posterior tibial perforator veins was also recorded (yes/no) tested by deep, selective palpation at the site where the perforator vein traverses the muscular fascia. Eating disorders were assessed with the SCOFF questionnaire (0-5) (40) (Table S5) and the Eating Attitude Test-40 (EAT-40) (0-120) (39) (see supplementary material). Fine sensory loss or tactile hypoesthesia at the petrochanteric region was evaluated using a pine brush (Figure 1).

Segmental multifrequency bioelectrical impedance analyses were performed, from which the following parameters were obtained: total body fat mass (BFM) (kg), percentage of body fat to total weight (%), fat mass of the right lower limb (kg), percentage of fat mass relative to total mass of the right lower limb (%), fat mass of the left lower limb (kg), and percentage of fat mass relative to total mass of the left lower limb (%).

To classify patients with lipedema according to the involvement of body segments, the Schingale classification was applied (42): type I, type II, type III, type IV, and type V (see supplementary material). To classify patients based on adipose tissue involvement and skin texture, the Schmeller classification was used (43): stage/grade I, stage/grade II, and stage/grade III (see supplementary material). In addition, affected areas of lipedema were assessed clinically, by ultrasound, and by elastographic evaluation of the GSphC, divided into proximal and distal segments. Strain elastography was used for this purpose (Table 1). As an ultrasound marker of lymphatic involvement, the presence of pretibial (stone-paved sign) (44) was evaluated in the distal tibia region (see supplementary material).

Table 1. Areas and type of evaluation of lipedema on the patient's body.

| Areas Affected by Lipedema | According to Clinic | Lipedematous Involvement. Ultrasound Sign of a "Snowstorm" | Elastographic Involvement of the Saphenous Compartment Greater Decrease in Elasticity | Lymphatic Involvement Ultrasound Sign (Stone-paved Sign) |
|----------------------------|---------------------|--|---|--|
| Infraumbilical abdomen | Not applicable | Yes/No | Not applicable | Not applicable |
| Hips | Yes/No | Yes/No | Not applicable | Not applicable |
| Upper half of thigh | Yes/No | Yes/No | Yes/No | Yes/No |
| Lower half of thigh | Yes/No | Yes/No | Yes/No | Yes/No |

| | | | | |
|----------------------------------|--------|----------------|----------------|----------------|
| Upper half of the calf | Yes/No | Yes/No | Yes/No | Yes/No |
| Lower half of the calf | Yes/No | Yes/No | Yes/No | Yes/No |
| Proximal half of the arm | Yes/No | Not applicable | Not applicable | Not applicable |
| Distal half of the arm (forearm) | Yes/No | Not applicable | Not applicable | Not applicable |
| Feet below the ankle | Yes/No | Not applicable | Not applicable | Yes/No |

All patients underwent Doppler ultrasound with particular attention to the great saphenous vein (GSV) and its perforator veins. The presence of saphenous insufficiency was assessed. Even in patients without insufficiency or signs of perforator damage, such as a diameter greater than 3.5 mm or bidirectional flow, selective digital pressure was performed at the site where the perforator vein crossed the deep (muscular) fascia, and the presence or absence of pain during this maneuver was recorded.

The sample size of this study was based on convenience, including all patients who met the inclusion criteria and attended the Instituto del Lipedema y de la Mujer clinics during the study period.

All patients included in the study provided written informed consent for the use of their data for research and scientific dissemination during their diagnostic visit. The study was approved by the Regional Research Ethics Committee for Medicinal Products of the Community of Madrid in April 2025 (Code: LIPE-2024-01).

2.2. Statistical Analysis

A descriptive analysis was performed for sociodemographic and clinical variables. Normally distributed numerical variables were expressed as means and standard deviations (SD), while non-normally distributed variables were reported as medians and interquartile ranges (IQR, 25th–75th percentile). Associations between saphenous compartment involvement, stone-paved sign, age, weight, obesity type, and fat distribution were analyzed using bivariate Pearson correlations. Results are presented as Pearson correlation coefficients (r) with the corresponding level of statistical significance (p -value). Correlations were considered moderate for r values between 0.3 and 0.5 and strong for r values between 0.5 and 0.9.

All statistical analyses were performed using SPSS version 26.

3. Results

A total of 1,846 patients were initially included in the study, of whom 43 were excluded from the analysis (2 men, 12 patients with incorrect age records, and 29 without a clinical diagnosis of lipedema), leaving a total of 1,803 patients.

3.1. General Descriptive Data and Clinical Signs of Lipedema on Physical Examination

The mean age of patients was 42.9 years (SD: 11.3), ranging from 18 to 94 years. Of the cohort, 60.6% (1,093) were of reproductive age (18–45 years), and 25.9% (467) were in the perimenopausal or menopausal age range (45–55 years). Regarding anthropometric parameters, the mean weight was 75 kg (SD: 16.4), mean height was 162 cm (SD: 6.3), and mean BMI was 28.6 (SD: 6.2). Overall, 31.9% (576) of patients were of normal weight, while 5.4% (98) had morbid or extreme obesity. In terms of body fat distribution, 87.8% (1,583) exhibited a gynoid pattern.

Total BFM was measured via bioelectrical impedance in 1,775 patients, with a mean of 27.7% (SD: 11.8) and a mean fat percentage relative to total body weight of 34.4% (SD: 9.8). Analysis of fat

percentage by anatomical segments showed no significant differences between the left and right sides, but significant differences were observed between upper and lower body segments (Table 2).

Table 2. General Description and Physical Examination of Patients with Lipedema.

| Variables | Total (n=1803) |
|---|----------------|
| Sociodemographic | |
| Age, mean (SD) | 42.9 (11.3) |
| Anthropometric | |
| Weight (kg), mean (SD) | 75 (16.4) |
| Height (cm), mean (SD) | 162 (6.3) |
| Body Mass Index (kg/m ²), mean (SD) | 28.6 (6.2) |
| Obesity | |
| Normal weight, n (%) | 576 (31.9%) |
| Overweight type 1, n (%) | 273 (15.1%) |
| Overweight type 2, n (%) | 288 (16%) |
| Obesity type 1, n (%) | 382 (21.2%) |
| Obesity type 2, n (%) | 182 (10.1%) |
| Obesity type 3 (Morbid), n (%) | 90 (5%) |
| Obesity type 4 (Extreme), n (%) | 8 (0.4%) |
| Underweight, n (%) | 4 (0.2%) |
| Fat distribution pattern | |
| Android, n (%) | 220 (12.2%) |
| Gynoid, n (%) | 1583 (87.8%) |
| Bioimpedance analysis | |
| Total Body Fat Mass (%), mean (SD) | 27.7 (11.8) |
| Percentage of body fat relative to total body weight (%), mean (SD) | 34.4 (9.8) |
| Percentage of fat in the lower right limb (%), mean (SD) | 5.2 (2.1) |
| Percentage of body weight of the lower right limb (%), mean (SD) | 37.5 (9.2) |
| Percentage of fat in the lower left limb (%), mean (SD) | 5.1 (2) |
| Percentage of body weight of the lower left limb (%), mean (SD) | 37.5 (9.3) |
| Physical examination | |
| Deep pressure pain in the Great Saphenous Compartment (upper half), n (%) | 1780 (98.7%) |
| Deep pressure pain in the Great Saphenous Compartment (lower half), n (%) | 1775 (98.4%) |
| Deep pressure pain in the Small Saphenous Compartment, n (%) | 1738 (96.4%) |
| Superficial pressure pain in the Brachial Compartment, n (%) | 1443 (80%) |
| Tender points | |
| Internal supracondylar, n (%) | 1781 (98.8%) |
| Internal infracondylar, n (%) | 1785 (99%) |
| Internal supramalleolar, n (%) | 1750 (97.1%) |
| Supraolecranon, n (%) | 1474 (81.8%) |
| False puncture Internal supracondylar, n (%) | 1758 (97.5%) |
| False puncture Internal supramalleolar, n (%) | 1730 (96%) |
| False puncture Supraolecranian, n (%) | 1411 (78.3%) |
| Loss of fine sensation at the pertrochanteric level, n (%) (n=195) | 176 (90.3%) |
| Kaposi-Stemmer sign | |
| Positive, n (%) | 138 (7.7%) |
| Equivocal, n (%) | 63 (3.5%) |
| Internal supramalleolar edema, n (%) (n=256) | 229 (89.5) |

| | |
|---|-------------|
| Internal supramalleolar pitting edema, n (%) (n=1749) | 97 (5.5%) |
| Pretibial edema, n (%) (n=293) | 259 (88.4%) |
| Pretibial pitting edema, n (%) (n=270) | 156 (57.8%) |

SD: Standard Deviation.

On physical examination, pressure-induced pain was more prevalent in the lower limbs than in the upper limbs. Deep pressure pain in the proximal and distal thirds of the GSphC was present in 98.7% (1,780) and 98.4% (1,775) of patients, respectively. Similarly, deep pressure pain in the SSphC was observed in 96.4% (1,738) of patients, while superficial pressure pain in the PBC was confirmed in 80% (1,443) of patients. Regarding specific tender points (medial supracondylar and infracondylar, medial supramalleolar, and supra-olecranon), they were positive in nearly all patients. The pseudo-pinch sign at the medial supracondylar, medial supramalleolar, and supra-olecranon sites was present in 97.5% (1,758), 99% (1,785), and 78.3% (1,474) of patients, respectively.

Fine sensory loss at the pertrochanteric region was only assessed in 195 patients and was positive in 90.3% (176) of them. The Kaposi-Stemmer sign was positive in 7.7% (138) of patients and indeterminate in 3.5% (63).

The presence of edema was also evaluated. Medial supramalleolar edema with pitting was very rare. In contrast, pretibial distal edema was present in 88.4% (259) of cases, and with pitting, generally grade 1, observed in a much lower percentage (57.8%). These signs could only be assessed in 293 and 270 patients, respectively. Medial distal supramalleolar edema was, with pitting edema generally grade 1, evaluated in a smaller subset of patients (n = 256) and was positive in 89.5% of them (Table 2).

Associations between saphenous compartment involvement, the pseudo-pinch sign, and fine sensory loss at the pertrochanteric region with age, weight, obesity type, and fat distribution pattern were weak ($r < 0.3$). In contrast, strong correlations ($r \geq 0.5$) were observed between deep pressure pain in the saphenous compartment, tender points, and pseudo-pinch signs, as shown in Table 3.

Table 3. Correlations between saphenous compartment signs, obesity, fat distribution pattern, age, and weight.

| | | Fat | | | | | | | | | | IS | IM | SO | PFS | Weight | Age |
|--------------------------|---|----------|----------------------|----------|----------|----------|---------|-----------|-----------|-----------|----------|----------------|----------------|----------------|-------|--------|-------|
| | | Obesity | Distribution pattern | GSC Pain | ISC Pain | SSC Pain | BC Pain | ISC Point | IIC Point | ISM Point | SO Point | False Puncture | False Puncture | False Puncture | | | |
| Obesity | r | 1 | | | | | | | | | | | | | | | |
| | p | 0,000 | 0,009 | 0,008 | 0,000 | 0,000 | 0,062 | 0,024 | 0,001 | 0,000 | 0,043 | 0,017 | 0,000 | 0,380 | 0,000 | 0,000 | |
| Fat distribution pattern | r | -0,315** | 1 | | | | | | | | | | | | | | |
| | p | 0,000 | 0,440 | 0,161 | 0,054 | 0,000 | 0,385 | 0,891 | 0,811 | 0,000 | 0,827 | 0,438 | 0,000 | 0,906 | 0,000 | 0,000 | |
| GSC pain | r | 0,061** | 0,018 | 1 | | | | | | | | | | | | | |
| | p | 0,009 | 0,440 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,002 | 0,022 | 0,172 | |
| ISC pain | r | 0,062** | -0,033 | 0,545** | 1 | | | | | | | | | | | | |
| | p | 0,008 | 0,161 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,743 | 0,157 | 0,667 | |
| SSC pain | r | 0,087** | -0,045 | 0,346** | 0,525** | 1 | | | | | | | | | | | |
| | p | 0,000 | 0,054 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,167 | 0,000 | 0,743 | |
| BC pain | r | 0,251** | -0,097** | 0,141** | 0,139** | 0,264** | 1 | | | | | | | | | | |
| | p | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,461 | 0,000 | 0,006 | |
| ISC point | r | 0,044 | 0,020 | 0,708** | 0,517** | 0,328** | 0,083** | 1 | | | | | | | | | |
| | p | 0,062 | 0,385 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,743 | 0,041 | 0,965 | |
| IIC point | r | 0,053* | -0,003 | 0,635** | 0,619** | 0,396** | 0,131** | 0,599** | 1 | | | | | | | | |
| | p | 0,024 | 0,891 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,027 | 0,997 |
| ISM point | r | 0,075** | -0,006 | 0,444** | 0,636** | 0,503** | 0,156** | 0,514** | 0,506** | 1 | | | | | | | |
| | p | 0,001 | 0,811 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,006 | 0,007 | 0,098 | |
| SO point | r | 0,237** | -0,105** | 0,125** | 0,173** | 0,252** | 0,885** | 0,117** | 0,140** | 0,195** | 1 | | | | | | |
| | p | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,682 | 0,000 | 0,002 | |
| IS False puncture | r | 0,048* | -0,005 | 0,362** | 0,354** | 0,253** | 0,116** | 0,371** | 0,485** | 0,306** | 0,099** | 1 | | | | | |
| | p | 0,043 | 0,827 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,569 | 0,204 | 0,311 | |
| IM | r | 0,056* | 0,018 | 0,303** | 0,429** | 0,350** | 0,151** | 0,259** | 0,404** | 0,509** | 0,143** | 0,544** | 1 | | | | |
| | p | 0,043 | 0,827 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,000 | 0,569 | 0,204 | 0,311 |

| | |
|---|--------------|
| Abdomen | 2 (0.1%) |
| Hips | 11 (0.6%) |
| Upper thigh | 1765 (97.9%) |
| Lower thigh | 1761 (97.7%) |
| Upper calf | 1728 (95.9%) |
| Lower calf | 1700 (94.3%) |
| Diagnosis based on elastographic involvement of the great saphenous vein compartment, n (%) (n=1802) | |
| Upper thigh | 1789 (99.3%) |
| Lower thigh | 1761 (97.7%) |
| Upper calf | 1356 (75.2%) |
| Lower calf | 1119 (62.1%) |
| Diagnosis based on the "Stone-paved sign" ultrasound sign, n (%) (n=1802) | |
| Upper thigh | 2 (0.1%) |
| Lower thigh | 1 (0.1%) |
| Upper calf | 164 (9.1%) |
| Lower calf | 851 (47.2%) |
| Feet below the ankle | 125 (6.9%) |

Pretibial stone-paved sign tissue below the ankle showed a moderate correlation with pretibial stone-paved sign tissue in the upper calf ($r = 0.41$; $p < 0.001$). Pretibial stone-paved sign tissue on ultrasound in the lower calf was moderately correlated with more extensive lipedema according to the Schingale classification ($r = 0.376$; $p < 0.001$). Furthermore, patients with higher body weight tended to exhibit more extensive lipedema ($r = 0.487$; $p < 0.001$) and higher stages according to adipose tissue involvement and skin texture ($r = 0.541$; $p < 0.001$) (Table 5).

Table 5. Correlations between the Stone-paved sign, lipedema classifications, age and weight.

| | | Stone-Paved Sign UT | Stone-Paved Sign LT | Stone-Paved Sign UC | Stone-Paved Sign LC | Stone-Paved Sign Below the Ankle | Classification of Schingale | Classification of Schmeller | Age | Weight |
|----------------------------------|---|---------------------|---------------------|---------------------|---------------------|----------------------------------|-----------------------------|-----------------------------|--------|--------|
| Stone-paved sign UT | r | 1 | -0.001 | -0.011 | 0.002 | -0.009 | 0.028 | -0.011 | 0.020 | 0.003 |
| | p | | 0.973 | 0.655 | 0.937 | 0.699 | 0.237 | 0.640 | 0.408 | 0.893 |
| Stone-paved sign LT | r | -0.001 | 1 | -0.007 | 0.025 | -0.006 | 0.020 | 0.032 | -0.023 | .055* |
| | p | 0.973 | | 0.752 | 0.291 | 0.785 | 0.403 | 0.183 | 0.334 | 0.020 |
| Stone-paved sign UC | r | -0.011 | -0.007 | 1 | .319** | .410** | .221** | .224** | .107** | .284** |
| | p | 0.655 | 0.752 | | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Stone-paved sign LC | r | 0.002 | 0.025 | .319** | 1 | .272** | .376** | .287** | .147** | .353** |
| | p | 0.937 | 0.291 | 0.000 | | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Stone-paved sign below the ankle | r | -0.009 | -0.006 | .410** | .272** | 1 | .123** | .173** | 0.027 | .176** |
| | p | 0.699 | 0.785 | 0.000 | 0.000 | | 0.000 | 0.000 | 0.257 | 0.000 |
| | r | 0.028 | 0.020 | .221** | .376** | .123** | 1 | .388** | .167** | .487** |

| | | | | | | | | | |
|-----------------------------|---|--------|--------|--------|--------|--------|--------|--------|--------|
| Classification of Schingale | p | 0.237 | 0.403 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Classification of Schmeller | r | -0.011 | 0.032 | .224** | .287** | .173** | .388** | 1 | .198** |
| | p | 0.640 | 0.183 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| Age | r | 0.020 | -0.023 | .107** | .147** | 0.027 | .167** | .198** | 1 |
| | p | 0.408 | 0.334 | 0.000 | 0.000 | 0.257 | 0.000 | 0.000 | 0.000 |
| Weight | r | 0.003 | .055* | .284** | .353** | .176** | .487** | .541** | .094** |
| | p | 0.893 | 0.020 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |

UT: upper thigh; LT: lower thigh; UC: upper calf; LC: lower calf; r: Pearson correlation; p: statistical significance level. *. The correlation is significant at the 0.05 level (two-tailed). **. The correlation is significant at the 0.01 level (two-tailed).

3.3. Comorbidities and Lipedema

The most frequent comorbidities in patients with lipedema (Table 6) were intestinal hyperpermeability (99%; 1,785) and symptoms related to ligamentous hyperlaxity (95.8%; 1,726), including bilateral trochanteritis (97.4%; 1,753) and iliotibial band involvement (96.6%; 1,737). The mean Beighton score (0–9) was 7.5 (SD: 1.6). Endocrine disorders, notably inflammatory ovarian dysfunction and thyroid disease, were present in 76% (1,368) and 59.5% (1,073) of patients, respectively. Among the 533 patients who underwent thyroid ultrasound to classify the type of involvement, 473 (88.7%) were found to have thyroid nodules. Nickel skin allergy was assessed in 130 patients, of whom 88 (67.7%) were positive. Pain in paratibial and posterior tibial perforator veins was present in 95% of patients for whom this information was recorded (519 paratibial and 516 posterior tibial), whereas Doppler ultrasound revealed involvement of the saphenous vein in only 9.1% (46/538) of cases. Other health issues examined included psychological impact related to eating disorders. The SCOFF test (0–5) showed a median score of 2 [IQR: 1–3], while the EAT-40 questionnaire (0–120) yielded a median of 21 [IQR: 14–30].

Table 6. Comorbidities in lipedema.

| Variables | Total |
|---|--------------|
| Intestinal hyperpermeability, n (%) | 1785 (99%) |
| Ligamentous hyperlaxity syndrome, n (%) (n=1801) | 1726 (95.8%) |
| Beighton test (0-9), media (DE) | 7.5 (1.6) |
| Bilateral trochanteritis, n (%) (n=1799) | 1753 (97.4%) |
| Iliotibial band involvement (Tensor fascia lata), n (%) (n=1799) | 1737 (96.6%) |
| Non-dislocated, recurrent ankle sprains due to mechanical instability, n (%) (n=1798) | 1106 (61.5%) |
| Nickel allergy, n (%) (n=130) | 88 (67.7%) |
| Thyroid pathology, n (%) (n=1801) | 1073 (59.5%) |
| Type of thyroid pathology, n (%) (n=533) | |
| Thyroid nodules | 473 (88.7%) |
| Multinodular goitre | 46 (8.6%) |
| Hypothyroidism | 13(2.4%) |
| Hashimoto's syndrome | 1 (0.2%) |
| Inflammatory ovarian dysfunction, n (%) (n=1801) | 1368 (76%) |
| Great saphenous vein, on Doppler ultrasound observation, n (%) (n=538) | 46 (9.1%) |
| Pain in paratibial perforators, n (%) (n=543) | 519 (95.6%) |
| Pain in post-tibial perforators, n (%) (n=538) | 516 (95.9%) |
| Treatment with psychologist, n (%) (n=531) | 329 (62%) |

| | |
|---------------------------------------|------------|
| Scoff test (0-5), median [p25-p75] | 2 [1-3] |
| Test EAT-40 (0-120), median [p25-p75] | 21 [14-30] |

EAT: Eating Attitudes Test.

4. Discussion

The results of this study derive from one of the largest published cohorts of patients with lipedema to date (over 1,800 women), in which a comprehensive physical examination of signs and symptoms was conducted alongside a detailed anamnesis of comorbidities associated with the disease. Two findings were identified that we consider particularly important.

1.- Since 2020 and throughout the inclusion period (January 2022–November 2024), we have proposed that increased intestinal permeability, accompanied by LPS-induced endotoxemia and potential microbial translocation, acts as an inflammatory trigger for lipedema. Subsequent publications support this hypothesis (45, 46). Given the limited feasibility to perform the physiological gold standard (segmental multi-sugar tests), we operationalized this hypothesis via a clinical questionnaire designed to identify a phenotype compatible with barrier dysfunction. In our cohort, 99% of patients exceeded the prespecified cutoff, suggesting a high burden of compatible symptoms and supporting this idea. This questionnaire does not diagnose increased permeability or endotoxemia, nor does it replace physiological testing; however, it provides evidence-based items to approximate the concept of intestinal permeability, which will require formal validation in future studies.

These results are consistent with the high prevalence of increased intestinal permeability and its link to chronic low-grade inflammation, which could be associated with, or even act as a triggering factor for, lipedema. However, our study does not allow us to establish causal relationships. Rather, it provides a description of the distribution of these health problems among our patients and supports the generation of causal hypotheses, which will require confirmation in future observational and controlled studies.

2.- In this study nearly all patients were found to have ligamentous hyperlaxity, with a high rate of positivity on the Beighton test (95.8% of 1,726 patients),

In addition to the Beighton score, we assessed accessory signs of ligamentous hyperlaxity supported by the literature: digital pressure pain over the iliotibial band/TFL (facial alterations in hEDS), bilateral trochanteric pain (GTPS) with a high prevalence of hypermobility, and lateral ankle instability with recurrent torsion without sprain due to ATFL/CFL laxity. These signs showed high positivity (ITB/TFL 96%, trochanteric pain 97%, recurrent torsion 61%), consistent with the literature on biomechanics and laxity in HSD/hEDS and CAI (47-53). This may suggest that lipedema is accompanied by connective tissue impairment, which could be one of its triggering factors. Such a mechanism might also explain the onset of lipedema before puberty, when estrogen is not yet present (54-56). Connective tissue damage may likewise account for the high percentage of patients in our cohort who presented with pain upon digital pressure of the pre- and paratibial perforators, likely due to impaired drainage with pathological centrifugal flow into the GSV. In our clinical experience, perforators in the femoral canal (Dodd) and adductor canal (Hunter) also elicit pain on digital pressure (unpublished data). Exploration of these tender points is not usually performed in routine clinical practice for diagnosing chronic venous insufficiency (CVI), where ultrasound is the main diagnostic tool. Remarkably, despite the fact that nearly all patients in our study exhibited pain upon examination of the perforators, only 9.1% of the 538 women who underwent Doppler ultrasound of the GSV were diagnosed with this condition (CVI). We hypothesize that the antireflux closure mechanism of the perforator veins that penetrate the muscular fascia obliquely (57,58), including both the Doppler-visible perforators and the many small, non-visible perforators (59), the smallest being valveless (60), is entirely or partially dependent on stretching of the muscular fascia (57,61). This mechanism may fail as a consequence of connective tissue damage associated with lipedema, leading to a pathological but subclinical outward flow that cannot be detected by Doppler ultrasound (62-64).

Another noteworthy finding is that women with more extensive lipedema showed evidence of lymphatic involvement, as indicated by positive ultrasound of a Stone-paved sign in the lower pretibial zone, similar to those observed in lymphedema (65-67), though less pronounced on ultrasound. In our experience, they are seen in the distal pretibial region in a suprapariosteal location.

We also observed that in nearly 40% of women in our study, lipedema was diagnosed at later ages (perimenopause, menopause, or postmenopause), suggesting a significant diagnostic delay. This finding is consistent with several previous studies, such as the 10-year retrospective cohort by Ghods M. et al. (68), which reported substantial delays in both diagnosis and treatment initiation, in some cases extending up to 18 years from the onset of symptoms, as described by Romeijn JRM (69). Similarly, in the study by Falck et al. (8), approximately 70% of women experienced symptom onset before the age of 30, yet only three patients (1.6%) received a diagnosis prior to that age. In the Spanish cohort, more than 40% of women were classified as having advanced stages of the disease (Schingale classification types IV and V), indicating that the condition was already highly progressed at the time of diagnosis, with all the associated consequences of poorer physical health and greater limitations in daily life (8). Altogether, these findings underscore the urgent need for early and timely diagnosis of lipedema, beginning at the primary care level, by family and community physicians, and extending to other specialists consulted for the multiple associated comorbidities.

Regarding comorbidities, inflammatory ovarian dysfunction was diagnosed in 76% of patients, a figure markedly higher than the prevalence of polycystic ovary syndrome reported in the Italian cohort by Patton et al. (70), which was 17.1%. Thyroid disease was identified in more than half of the patients, also well above the prevalence reported by Patton et al. (70), where 22.5% of patients had hypothyroidism. When thyroid involvement was assessed by ultrasound findings, the prevalence was even higher, with thyroid nodules observed in 88.7% of patients. These discrepancies across studies may partly reflect variability in the definitions employed; however, the differences remain striking. It has been suggested that increased intestinal hyperpermeability and the resulting state of chronic low-grade inflammation may contribute to the development of autoimmune diseases (71-75).

In future clinical studies on lipedema, both thyroid ultrasound and Doppler imaging should be systematically performed. These assessments should also be considered in the pre-surgical setting.

Another noteworthy finding is the high prevalence of nickel skin allergies among our patients, which should not be confused with systemic allergies. Many patients reported that, both in childhood and currently, wearing costume jewelry led to irritation of the earlobe or other areas in contact with nickel-containing objects. Although this condition could only be assessed in a relatively small subset of our cohort, the prevalence observed was substantially higher than that reported in the general population, where estimates are around 24% (76).

Another comorbidity frequently observed in these patients is related to mental health. Patients demonstrated a high risk of developing eating disorders, findings consistent with previous reports indicating that women with lipedema have higher rates of anxiety, depression, and eating disorders, particularly in the more advanced stages of the disease (16). These conditions appear to develop as compensatory mechanisms, largely due to the frequent misclassification of lipedema as obesity (77).

In the present study, we identified signs and symptoms of lipedema in a cohort of more than 1,800 patients. However, given the lack of a healthy control group, it is not possible to establish definitive diagnostic criteria for the disease. Nevertheless, considering the very high prevalence of these signs and symptoms (ranging from 88% to 98%) in such a large number of diagnosed patients, we propose that the absence of these findings may help to rule out lipedema.

Regarding study limitations, the study design itself does not allow for establishing causal or prognostic relationships in lipedema; however, it does enable the generation of causal hypotheses by describing the distribution of a large number of symptoms, signs, and comorbidities associated with lipedema in a sizable patient cohort. Another limitation of the present study is the lack of validated questionnaires for assessing intestinal permeability and ligamentous hyperlaxity. Despite these limitations, the results are highly promising, as they provide, for the first time, a comprehensive description of findings related to involvement of the saphenous compartment, connective tissue

alterations, and intestinal hyperpermeability as possible causal or associated mechanisms of the disease. These findings underscore the need for continued research on this important health issue, using observational and controlled study designs to further understand the disease, its risk factors, prognostic indicators, and the efficacy and effectiveness of treatments to improve disease progression and the quality of life of affected patients.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org.

Author Contributions: Conceptualization, JLS, SM and MAMM.; Methodology, JLS, SM and MAMM.; Investigation, JLS, SM and MAMM.; Formal Analysis, MAMM and JTSC.; Data Curation, JTSC.; Writing – Original Draft Preparation, JLS, SM, JTSC and MAMM.; Writing – Review & Editing, JLS, SM, MAG, ALG, DOA, JML, JBV, JTSC and MAMM.

Funding Information: No funding was received for this article.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by Regional Research Ethics Committee for Medicinal Products of the Community of Madrid in April 2025 (Code: LIPE-2024-01) on April 12, 2025].

Informed Consent Statement: Informed consent for participation was obtained from all subjects involved in the study.

Acknowledgments: The authors would like to express their gratitude to all study participants for their invaluable contribution. They also wish to extend their sincere appreciation to Francisco de Asís Simarro for his valuable assistance and insightful contributions to this research.

Author Disclosure Statement: The authors have no conflicts of interest with respect to this article.

References

1. Alcolea, J.M.; Alonso, A.B.; Arroyo, B.A.; Domingo, P.; Garcia, G.A.; Graells, G.M.; et al. Consensus Document on Lipedema 2018. *Includes Current Status of Lipedema*. **2019**; LITOGAMA SL: Barcelona, Spain, 2018.
2. Wold L.E.; Hine EA Jr., Allen E.V. Lipedema of the legs; a syndrome characterized by fat legs and edema. *Ann Intern Med*. **1951**, 34(5), 1243-50.
3. World Health Organization. International statistical classification of diseases and related health problems (11th Revision) <https://icd.who.int/browse/2025-01/mms/en#1172950828> Accessed 15 April 2025.
4. Priglinger E.; Wurzer C.; Steffenhagen C.; Maier J.; Hofer V.; Peterbauer A, Nuernberger S, Redl H, Wolbank S, Sandhofer M. The adipose tissue-derived stromal vascular fraction cells from lipedema patients: Are they different? *Cytotherapy*. **2017**, 19(7), 849-860.
5. Szél E.; Kemény L.; Groma G.; Szolnoky G. Pathophysiological dilemmas of lipedema. *Med Hypotheses*. **2014**, 83(5), 599-606.
6. Redondo Galán C.; García Bascones M.; Marquina Valero MA. Lipedema: clínica, diagnóstico y tratamiento. Revisión de la literatura [Lipoedema: Symptoms, diagnosis and treatment. A literature review]. *Rehabilitacion*. **2019**, 53(2), 104-110.
7. Mortada H.; Alhithlool A.W.; AlBattal N.Z.; Shetty R.K.; Al-Mekhlafi G.A.; Hong J.P.; Alshomer F. Lipedema: Clinical Features, Diagnosis, and Management. *Arch Plast Surg*. **2025**, 52(3), 185-196.
8. Falck J.; Rolander B.; Nygårdh A.; Jonasson L.L.; Mårtensson J. Women with lipoedema: a national survey on their health, health-related quality of life, and sense of coherence. *BMC Womens Health*. **2022**, 22(1),457.
9. Herbst K.L.; Kahn L.A.; Iker E.; Ehrlich C.; Wright T.; McHutchison L.; et al. Standard of care for lipedema in the United States. *Phlebology*. **2021**, 36(10), 779–96.
10. Reich-Schupke S.; Schmeller W.; Brauer W.J.; Cornely M.E.; Faerber G.; Ludwig M.; et al. S1 guidelines: Lipedema. *J Dtsch Dermatol Ges*. **2017**, 15(7), 758–67.

11. Monnin-Delhom E.D.; Gallix B.P.; Achard C.; Bruel J.M.; Janbon C. High resolution unenhanced computed tomography in patients with swollen legs. *Lymphology*. **2002**, 35(3), 121-8.
12. Luta X.; Buso G.; Porceddu E.; Psychogyiou R.; Keller S.; Mazzolai L. Clinical characteristics, comorbidities, and correlation with advanced lipedema stages: A retrospective study from a Swiss referral centre. *PLoS One*. **2025**, 20(3), e0319099.
13. Falck J.; Nygårdh A.; Rolander B.; Jonasson L.L.; Mårtensson J. Dealing with lipodema: women's experiences of healthcare, self-care, and treatments-a mixed-methods study. *BMC Womens Health*. **2025**, 25(1), 171.
14. Buso G.; Depairon M.; Tomson D.; Raffoul W.; Vettor R.; Mazzolai L. Lipedema: A Call to Action! *Obesity*. **2019**, 27(10):1567-1576.
15. Dudek J.E.; Białaszek W.; Ostaszewski P. Quality of life in women with lipodema: a contextual behavioral approach. *Qual Life Res*. **2016**, 25(2), 401-408.
16. Clarke C.; Kirby J.N.; Smidt T.; Best T. Stages of lipodema: experiences of physical and mental health and health care. *Qual Life Res*. **2023**, 32(1), 127-137.
17. Child A.H.; Gordon K.D.; Sharpe P.; Brice G.; Ostergaard P.; Jeffery S.; Mortimer P.S. Lipedema: an inherited condition. *Am J Med Genet A*. **2010**, 152A, 970-6.
18. Michelini S.; Chiurazzi P.; Marino V.; Dell'Orco D.; Manara E.; Baglivo M. et al. Aldo-Keto Reductase 1C1 (AKR1C1) as the First Mutated Gene in a Family with Nonsyndromic Primary Lipedema. *Int J Mol Sci*. **2020**, 21, 6264.
19. Klimentidis Y.C.; Chen Z.; Gonzalez-Garay M.L.; Grigoriadis D.; Sackey E.; Pittman A. et al. Genome-wide association study of a lipedema phenotype among women in the UK Biobank identifies multiple genetic risk factors. *Eur J Hum Genet*. **2023**, 31(3), 338-344.
20. Michelini S.; Herbst K.L.; Precone V.; Manara E.; Marceddu G.; Dautaj A. et al. A Multi-Gene Panel to Identify Lipedema-Predisposing Genetic Variants by a Next-Generation Sequencing Strategy. *J Pers Med*. **2022**, 12(2), 268.
21. Halk A.B.; Damstra R.J. First Dutch guidelines on lipedema using the international classification of functioning, disability and health. *Phlebology*. **2017**, 32(3), 152-159.
22. Aerenhouts D.; Clarys P.; Taeymans J.; Van Cauwenberg J. Estimating Body Composition in Adolescent Sprint Athletes: Comparison of Different Methods in a 3 Years Longitudinal Design. *PLoS One*. **2015**, 10(8), e0136788.
23. Losurdo G.; Principi M.; Iannone A.; Amoruso A.; Ierardi E.; Di Leo A.; Barone M. Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm. *World J Gastroenterol*. **2018**, 24(14),1521-1530.
24. Neroni B.; Evangelisti M.; Radocchia G.; Di Nardo G.; Pantanella F.; Villa M.P.; Schippa S. Relationship between sleep disorders and gut dysbiosis: what affects what? *Sleep Med*. **2021**, 87, 1-7.
25. Lee C.H.; Giuliani F. The Role of Inflammation in Depression and Fatigue. *Front Immunol*. **2019**, 10, 1696.
26. Cardoso-Silva D.; Delbue D.; Itzlinger A.; Moerkens R.; Withoff S.; Branchi F.; Schumann M. Intestinal Barrier Function in Gluten-Related Disorders. *Nutrients*. **2019**, 11(10), 2325.
27. Dantzer R.; O'Connor J.C.; Freund G.G.; Johnson R.W.; Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci*. **2008**, 9(1), 46-56.
28. Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. *Gut*. **2019**, 68(8),1516-1526.
29. Halmos E.P.; Power V.A.; Shepherd S.J.; Gibson P.R.; Muir J.G.; A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. *Gastroenterology*. **2014**, 146(1):67-75.e5.
30. Miglietta S.; Borghini R.; Relucanti M.; Sorrentino V.; Chen R.; Li X.; Fazi F.; et al. New Insights into Intestinal Permeability in Irritable Bowel Syndrome-Like Disorders: Histological and Ultrastructural Findings of Duodenal Biopsies. *Cells*. **2021**, 10(10), 2593.
31. Staudacher H.M.; Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. *Gut*. **2017**, 66(8),1517-1527.
32. Guo P.; Wang H.; Ji L.; Song P.; Ma X. Impacts of Fructose on Intestinal Barrier Function, Inflammation and Microbiota in a Piglet Model. *Nutrients*. **2021**, 13(10), 3515.

33. Lombardi F.; Fiasca F.; Minelli M.; Maio D.; Mattei A.; Vergallo I.; et al. The Effects of Low-Nickel Diet Combined with Oral Administration of Selected Probiotics on Patients with Systemic Nickel Allergy Syndrome (SNAS) and Gut Dysbiosis. *Nutrients*. **2020**, 12(4), 1040.
34. Portincasa P.; Bonfrate L.; Khalil M.; Angelis M.; Calabrese F.M.; D'Amato M.; et al. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. *Biomedicines*. **2021**, 10(1), 83.
35. Beighton P.; Solomon L.; Soskolne CL. Articular mobility in an African population. *Ann Rheum Dis*. **1973**, 32(5), 413–418.
36. Zhai J.; Vannuccini S.; Petraglia.; F. Giudice L.C. Adenomyosis: Mechanisms and Pathogenesis. *Semin Reprod Med*. **2020**, 38(2-03), 129-143.
37. Jain V.; Chodankar R.R.; Maybin J.A.; Critchley HOD. Uterine bleeding: how understanding endometrial physiology underpins menstrual health. *Nat Rev Endocrinol*. **2022**, 18(5), 290-308.
38. Velez L.M.; Seldin M.; Motta A.B. Inflammation and reproductive function in women with polycystic ovary syndrome†. *Biol Reprod*. **2021**, 104(6), 1205-1217
39. Castro J.; Toro J.; Salamero M.; Guimerá E. The Eating Attitudes Test: validation of the Spanish version. *Psicothema*. **1991**, 3(3), 395–403.
40. Garcia-Campayo J.; Sanz-Carrillo C.; Ibañez J.A.; Lou S.; Solano V.; Alda M. Validation of the Spanish version of the SCOFF questionnaire for the screening of eating disorders in primary care. *J Psychosom Res*. **2005**, 59(2), 51-5.
41. Herbst K.L. Rare adipose disorders (RADs) masquerading as obesity. *Acta Pharmacol Sin*. **2012**, 33(2),155–72.
42. Schingale F. Lymphödeme – Lipödeme: Diagnose und Therapie. Ein Ratgeber für Betroffene. Hannover: Schlütersche Verlagsgesellschaft. **2003**, 176 S.
43. Reich-Schupke S.; Schmeller W.; Brauer W.J.; Stücker M. Lipedema: new classification and diagnosis guidelines. *Phlebology*. **2021**, 36(4), 252-60.
44. Ricci V.; Ricci C.; Gervasoni F.; Giulio C.; Farì G.; Andreoli A. et al. From physical to ultrasound examination in lymphedema: a novel dynamic approach. *J Ultrasound*. **2022**, 25(3), 757-763.
45. Kruglikov I.L.; Scherer P.E. Pathophysiology of cellulite: Possible involvement of selective endotoxemia. *Obes Rev*. **2023**, 24(1), e13517.
46. Kruglikov I.L.; Scherer P.E. Is the endotoxin-complement cascade the major driver in lipedema? *Trends Endocrinol Metab*. **2024**, 35(9), 769-780.
47. Wang T.J.; Stecco A.; Schleip R.; Stecco C.; Pirri C. Change in gliding properties of the iliotibial tract in hypermobile Ehlers-Danlos Syndrome. *J Ultrasound*. **2023**, 26(4), 809-813.
48. Tinkle B.; Castori M.; Berglund B.; Cohen H.; Grahame R.; Kazkaz H. et al. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history. *Am J Med Genet C Semin Med Genet*. **2017**, 175(1), 48-69.
49. Reimer L.C.U.; Jacobsen J.S.; Mechlenburg I. Hypermobility among patients with greater trochanteric pain syndrome. *Dan Med J*. **2019**, 66(4), A5539.
50. Hou Z.C.; Ao Y.F.; Hu Y.L.; Jiao C.; Guo Q.W.; Li N. et al. Balance training benefits chronic ankle instability with generalized joint hypermobility: a prospective cohort study. *BMC Musculoskelet Disord*. **2023**, 24(1), 7.
51. Huang B.; Kim Y.T.; Kim J.U.; Shin J.H.; Park Y.W.; Kim H.N.; Modified Broström Procedure for Chronic Ankle Instability With Generalized Joint Hypermobility. *Am J Sports Med*. **2016**, 44(4), 1011-6.
52. Chen H.; Zeng X.; Xie Z.; Ma L.; Zhong G.; Li L. et al. Kinematic alterations of the ankle in subjects with generalized joint hypermobility compared with the controls: A cross-sectional study. *J Orthop Surg (Hong Kong)*. **2022**, 30(3), 10225536221125951.
53. Croy T.; Saliba S.A.; Saliba E.; Anderson M.W.; Hertel J. Differences in lateral ankle laxity measured via stress ultrasonography in individuals with chronic ankle instability, ankle sprain copers, and healthy individuals. *J Orthop Sports Phys Ther*. **2012**, 42(7), 593-600.
54. Schook C.C.; Mulliken J.B.; Fishman S.J.; Alomari A.I.; Grant F.D.; Greene A.K. Differential diagnosis of lower extremity enlargement in pediatric patients referred with a diagnosis of lymphedema. *Plast Reconstr Surg*. **2011**, 127(4), 1571-1581.

55. Maclellan R.A.; Couto R.A.; Sullivan J.E.; Grant F.D.; Slavin S.A.; Greene A.K. Management of Primary and Secondary Lymphedema: Analysis of 225 Referrals to a Center. *Ann Plast Surg.* **2015**, *75*(2), 197-200.
56. Romeijn JR.M.; de Rooij MJ.M.; Janssen L.; Martens H. Exploration of Patient Characteristics and Quality of Life in Patients with Lipoedema Using a Survey. *Dermatol Ther.* **2018**, *8*, 303–311.
57. Askar O.; Kassem KA. A radiological study of the effect of the deep fascia on the communicating veins of the leg. *Br J Radiol.* **1963**, *36*, 583-5.
58. Chung J.H.; Heo S. Varicose Veins and the Diagnosis of Chronic Venous Disease in the Lower Extremities. *J Chest Surg.* **2024**, *5*, 57(2), 109-119.
59. Sannikov A.B.; Emel'ianenko V.M.; Solokhin S.A.; Rachkov M.A.; Drozdova I.V.; Shaĭdakov EV. Sviaz' perforantnykh i vnutrimyshechnykh ven goleni pri varikoznoĭ bolezni. *Angiol Sosud Khir.* **2021**, *27*(2), 73-81.
60. Kachlik D.; Pechacek V.; Hnatkova G.; Hnatek L.; Musil V.; Baca V. The venous perforators of the lower limb - A new terminology. *Phlebology.* **2019**, *34*(10), 650-668.
61. Baliyan V.; Tajmir S.; Hedgire S.S.; Ganguli S.; Prabhakar A.M. Lower extremity venous reflux. *Cardiovasc Diagn Ther.* **2016**, *6*(6), 533-543.
62. Recek C. Competent and incompetent calf perforators in primary varicose veins: a resistant myth. *Phlebology.* **2015**, *31*(8), 532-540.
63. Sarin S.; Scurr J.H.; Smith P.D. Medial calf perforators in venous disease: the significance of outward flow. *J Vasc Surg.* **1992**, *16*(1), 40-6.
64. Smith P.C. Noninvasive venous investigation. *Vascular Medicine Review.* **1990**, *1*(2), 139-166.
65. Niimi K.; Hirai M.; Iwata H.; Miyazaki K. Ultrasonographic findings and the clinical results of treatment for lymphedema. *Ann Vasc Dis.* **2014**, *7*(4), 369-75.
66. Rai P.; Mahajan A.; Shukla S.; Pokar N. Imaging and management of lymphedema in the era of precision oncology. *Br J Radiol.* **2025**, *98*(1169), 619-629.
67. Dimakakos P.B.; Stefanopoulos T.; Antoniadis P.; Antoniou A.; Gouliamos A.; Rizos D. MRI and ultrasonographic findings in the investigation of lymphedema and lipedema. *Int Surg.* **1997**, *82*(4):411-6.
68. Ghods M.; Georgiou I.; Schmidt J.; Kruppa P. Disease progression and comorbidities in lipedema patients: A 10-year retrospective analysis. *Dermatol Ther.* **2020**, *33*(6), e14534.
69. Romeijn JR.M.; de Rooij MJ.M.; Janssen L.; Martens H. Exploration of Patient Characteristics and Quality of Life in Patients with Lipoedema Using a Survey. *Dermatol Ther.* **2018**, *8*(2), 303-311.
70. Patton L.; Ricolfi L.; Bortolon M.; Gabriele G.; Zolesio P.; Cione E.; et al. Observational study on a large Italian population with lipedema: biochemical and hormonal profile, anatomical and clinical evaluation, self-reported history. *Int J Mol Sci.* **2024**, *25*(3), 1599.
71. Kinashi Y.; Hase K. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. *Front Immunol.* **2021**, *12*, 673708.
72. Mu Q.; Kirby J.; Reilly C.M.; Luo XM. Leaky Gut As a Danger Signal for Autoimmune Diseases. *Front Immunol.* **2017**, *8*, 598.
73. Rizzetto L.; Fava F.; Tuohy K.M.; Selmi C. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex. *J Autoimmun.* **2018**, *92*, 12-34.
74. Legakis I.; Chrousos G.P.; Chatzipanagiotou S. Thyroid Diseases and Intestinal Microbiome. *Horm Metab Res.* **2023**, *55*(12), 813-818.
75. Tywanek E.; Michalak A.; Świrska J.; Zwolak A. Autoimmunity, New Potential Biomarkers and the Thyroid Gland-The Perspective of Hashimoto's Thyroiditis and Its Treatment. *Int J Mol Sci.* **2024**, *25*(9), 4703.

76. García-Rabasco A.E.; Zaragoza-Ninet V.; García-Ruiz R.; de la Cuadra-Oyanguren J. Allergic contact dermatitis due to nickel: descriptive study in a tertiary hospital, 2000-2010. *Actas Dermosifiliogr.* **2014**, *105*(6), 590-6.
77. Wright T.F.; Herbst K.L. A Young Woman with Excessive Fat in Lower Extremities Develops Disordered Eating and Is Subsequently Diagnosed with Anorexia Nervosa, Lipedema, and Hypermobility Ehlers-Danlos Syndrome. *Am J Case Rep.* **2021**, *22*, e930840.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.